A Biotech CRO Company

Meet the members of ZeClinics

Our vision

ZeClinics is a Biotech Contract Research Organization (CRO) and early-phase biopharmaceutical (PHARMA) company using zebrafish (Danio rerio) for safety and efficacy screenings of novel chemical molecules. Our business strengths rely on high technical expertise and top-notch research facilities, combined with attractive strategic partnerships and academic collaborations.

We aim to challenge the traditional drug discovery pipeline by offering a cheap, fast, and reliable array of customized assays, to assess the safety and biomedical relevance of novel molecules using zebrafish. In a challenging economic environment, ZeClinics represents an excellent example of a business model that uses research and innovation as a way to success.

Our VALUES are:

Social impact, responsibility & ethics: we collaborate with society, transmitting our general knowledge to the people. Sustainability and ethics are always in our spotlight.

Working environment & intellectual freedom: we take care of all our employees, with a particular focus on the work environment and granting labor flexibility. We like people with a critical spirit and freedom of opinion.

Professional training, career & development: we invest efforts in training our staff to develop their careers in the best environment. We think it is a win-win.

Respect, fairness & justice: we are always on the side of non-discrimination and equal treatment, as well as parity in work. It is our commitment.

Vision, organization & excellence: we want to be the global reference in zebrafish drug discovery. Scientific excellence is our work guideline.


Why zebrafish?

More than 25.000 papers published have allowed zebrafish to become an essential tool for high-throughput screenings of small molecules with therapeutic effects. In that sense, both the academy and pharmaceutical industry use zebrafish to save time and money in pre-clinical studies for assessing toxicity and efficacy of new drugs in the fields of infection, cardiovascular diseases, neural disorders, or cancer. In summary, the advantages of using an animal model such as zebrafish for biomedicine and drug discovery are multiple:

i) Drugs are administered directly in their swimming water. This feature has two main advantages; first, it saves time in the procedure, if compared, for example, with the time invested in injecting drugs in mice. And second, it helps to understand how a molecule behaves in terms of ADME (Absorption, Distribution, Metabolism, and Excretion) when confronted with a biochemical or cell culture drug screening. Both of them, by nature, will give much-limited information in that regard.

ii) The small size and the high number of the zebrafish progeny allows the parallel and reproducible testing of several drugs and dosages in simple multiwell plates. Zebrafish reproduce quickly, producing 9,000 offspring in a lifetime, compared to only 300 offspring over a mouse's lifetime.

iii) Zebrafish share a high degree of conservation with humans in both their genome and their physiological processes (close to 80%). This fact permits to assess with certainty the possible toxicity or effects that a drug could have when administered to us.

iv) Zebrafish transparency, combined with a growing battery of fluorescent tissue-specific zebrafish transgenic lines, plus novel advances in imaging capture and processing, allows analyzing in vivo the effects of drugs in groups of cells or single tissues.

v) Zebrafish maintenance costs are less than 1/1000th of mice maintenance costs (zebrafish are small and social, with 70 individuals per tank, versus only five mice per cage).

All these features have allowed zebrafish to yield considerable advances in the fields of developmental biology, oncology, toxicology, reproductive studies, teratology, genetics, neurobiology, environmental sciences, stem cell research, and regenerative medicine, and evolutionary theory… and this is only the beginning!

Developing new drugs costs €500-1000 bn and takes 10-15 years. The pre-clinical phase is critical and expensive (30% total investment). Our solution for cutting time and budget is the use of zebrafish, an animal model that allows obtaining high-quality data in a fast and inexpensive manner.

Why high-quality data?

Zebrafish is a vertebrate whose genome is completely sequenced and who shares similar physiology to humans, including many equivalent organs. Zebrafish offers a growing battery of genetic tools, which, combined with organism’s transparency, permits the tracing of cells and easy genetic manipulation. These characteristics help ensure that information acquired through Danio rerio specimens is more accurate and informative than that obtained by in vitro assays, and thus easier to extrapolate to human biology.

Why fast and inexpensive?

Zebrafish maintenance is much less costly than other animal models traditionally used in chemical screenings. Its life cycle is faster, and it can provide hundreds of eggs in a single day. Because the animal is small and permeable to many chemicals dissolved in water, high-throughput screenings can be achieved using a tiny test compound, resulting in an enormous saving of time and resources.

Number of new approved drugs vs pharmaceutical R&D investment
Advantages of using zebrafish vs rodents

Founder team

Davide DAmico ZeClinics
Davide D’Amico, PhD (CEO)

Davide has extensive knowledge on the effects of several neuroactive drugs on a wide series of animal behaviors and central nervous system functions. He also has a long professional record in business management.

LinkedIn profile
Researchgate profile
Javier Terriente ZeClinics
Javier Terriente, PhD (CSO)

Javier is an international expert in zebrafish development and the exploitation of this animal model in pre-clinical assays. He has authored multiple articles on those subjects. Since the founding of the company, it is its scientific director.

LinkedIn profile
Researchgate profile
Ignasi Sahun ZeClinics
Ignasi Sahún, PhD (CMO)

Ignasi has a long experience in drug-treatment and analysis of different animal models for phenotypical characterization. He has published several articles on that topic. He also has extensive experiencie in branding and marketing strategy.

LinkedIn profile
Researchgate profile
Simone Calzolari ZeClinics
Simone Calzolari, PhD (CCO)

Simone is a senior expert in development biology, focused especially on the zebrafish model. On the other hand, he has a long record in commercial strategy and business development in CRO environment.

LinkedIn profile
Researchgate profile

Associated Partner

Miguel Ezcurra ZeClinics
Miguel Ezcurra, PhD ( CFO)

Miguel has +15 years working experience in the areas of asset management and corporate finance, having held multiple senior management positions for a number of international institutions.

LinkedIn profile


ZeClinics counts with a multidisciplinary team of talented scientists covering all different areas of drug discovery, from library screening up to lead generation (CRISPR) and validation, safety and efficacy assessment and zebrafish biology. Our skilled team can support your R&D project and make your research easy and fast. All our scientist staff hold a Ph.D. title and show the flexibility and ability acquired in both basic and applied research projects, with a full perspective on the business translation of science. Get to know them more closely through our posts and social profiles and our LinkedIn company page!



Germans Trias i Pujol Research Institute (IGTP)

The Germans Trias i Pujol Research Institute (IGTP) is a public research center in the Autonomous Region of Catalonia in Northern Spain dedicated to increasing scientific knowledge and transferring it to improve the care and lives of patients.

The institute is attached to one of the large teaching hospitals in the Barcelona area; the Germans Trias University Hospital (HUGTP), and is located on the biomedical campus that surrounds it, Campus Can Ruti.  It is a CERCA center; a member of the biocluster supported and supervised by the Autonomous Catalonian Government.  It is also accredited as a Centre of Excellence by the Instituto Carlos III (Spanish Government) and in this capacity acts as an umbrella organization for scientific research on the campus, where it works closely with the other centers located there

The Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) is a center dedicated to biomedical research and training; it was set up by the Germans Trias i Pujol Research Institute (IGTP). This new research infrastructure aims to become a reference center for comparative medicine, surgery, bioimaging, and computational models in Europe, while at the same time developing alternative research methods.

ZeClinics Headquarters

ZeClinics Headquarters

Barcelona is probably one of the most attractive biomedicine HUBs in Europe. The Mediterranean lifestyle, combined with an orderly city, safe, rich in culture and leisure activities, and with a perfect annual climate, make it the ideal place to develop business.

ZeClinics Headquarters (Marina 25) is located in the Olympic neighborhood of Barcelona, a few meters from the beach and in one of the nerve centers of the city. With 180 square meters of surface and with exceptional architectural design and several different work areas, it is the perfect space to develop our commercial and administrative activities.

ZeClinics is supported by Universitat Pompeu Fabra

Pompeu Fabra University (UPF)

ZeClinics worked several years under the umbrella of the Pompeu Fabra University (UPF), a young, public and modern university founded in 1990 and called to become one of the leading European universities.

Awarded with a CEI label (International Excellence Campus) by the Spanish Ministry of Education, UPF’s indicators have made it a benchmark for the Spanish and European university systems. In recent years, the University has begun to figure prominently in some prestigious international rankings.

These results are possible due to the high competitiveness of UPF lecturers and researchers. In that sense, the University model is primarily based on a policy of being an institution that is open to the world, incorporating prominent national and international researchers. This commitment is reflected in excellent indicators in research, such as the volume of funds coming from the EU – 7th Framework Programme (FP7) and H2020 - or indicators of scientific production.

Our Bio-environment

ZeClinics operates from the Bio-region of Catalonia, one of the most dynamics in Europe, with 90 public research centers and more than 400 life sciences academic groups. Private sector is conformed by more than 500 companies, including major international pharmaceutical companies like Almirall, Ferrer, Amgem, Bristol-Myers Squibb, Esteve, GlaxoSmithKline, Roche Group, Novartis, Pfizer, Sanofi-Aventis and Takeda, which represents the 29.4% of this economic sector volume and an estimated turnover of €15,600 m/year.